Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Liabilities and Shareholders Equity (2020 - 2023)

Candel Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $50.1 million for Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity fell 41.11% year-over-year to $50.1 million; the TTM value through Dec 2023 reached $176.0 million, down 50.78%, while the annual FY2022 figure was $77.7 million, 12.91% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2023 was $50.1 million at Candel Therapeutics, down from $58.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $101.6 million in Q1 2022 and bottomed at $30.7 million in Q2 2021.
  • The 4-year median for Liabilities and Shareholders Equity is $77.7 million (2022), against an average of $71.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 203.48% in 2022 before it crashed 41.11% in 2023.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $38.3 million in 2020, then soared by 133.02% to $89.2 million in 2021, then fell by 12.91% to $77.7 million in 2022, then crashed by 35.56% to $50.1 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Liabilities and Shareholders Equity are $50.1 million (Q3 2023), $58.7 million (Q2 2023), and $67.2 million (Q1 2023).